Viral Vectors for COVID-19 Vaccine Development

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2021 Mar 6

PMID 33669550

Citations 36

Authors

Kenneth Lundstrom

Affiliations

Soon will be listed here.

Abstract

Vaccine development against SARS-CoV-2 has been fierce due to the devastating COVID-19 pandemic and has included all potential approaches for providing the global community with safe and efficient vaccine candidates in the shortest possible timeframe. Viral vectors have played a central role especially using adenovirus-based vectors. Additionally, other viral vectors based on vaccinia viruses, measles viruses, rhabdoviruses, influenza viruses and lentiviruses have been subjected to vaccine development. Self-amplifying RNA virus vectors have been utilized for lipid nanoparticle-based delivery of RNA as COVID-19 vaccines. Several adenovirus-based vaccine candidates have elicited strong immune responses in immunized animals and protection against challenges in mice and primates has been achieved. Moreover, adenovirus-based vaccine candidates have been subjected to phase I to III clinical trials. Recently, the simian adenovirus-based ChAdOx1 vector expressing the SARS-CoV-2 S spike protein was approved for use in humans in the UK.

Citing Articles

Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.

Henriquez R, Munoz-Barroso I Heliyon. 2024; 10(15):e34927.

PMID: 39144987 PMC: 11320483. DOI: 10.1016/j.heliyon.2024.e34927.

Role of long noncoding RNAs in diabetes-associated peripheral arterial disease.

Tapia A, Liu X, Malhi N, Yuan D, Chen M, Southerland K Cardiovasc Diabetol. 2024; 23(1):274.

PMID: 39049097 PMC: 11271017. DOI: 10.1186/s12933-024-02327-7.

COVID-19 Vaccines: Where Did We Stand at the End of 2023?.

Lundstrom K Viruses. 2024; 16(2).

PMID: 38399979 PMC: 10893040. DOI: 10.3390/v16020203.

Biomaterials for Drug Delivery and Human Applications.

Trucillo P Materials (Basel). 2024; 17(2).

PMID: 38255624 PMC: 10817481. DOI: 10.3390/ma17020456.

Innovation-driven trend shaping COVID-19 vaccine development in China.

Zhang Y, Zhao Y, Liang H, Xu Y, Zhou C, Yao Y Front Med. 2023; 17(6):1096-1116.

PMID: 38102402 DOI: 10.1007/s11684-023-1034-6.

References

Sun W, Leist S, McCroskery S, Liu Y, Slamanig S, Oliva J . Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine. 2020; 62:103132. PMC: 7679520. DOI: 10.1016/j.ebiom.2020.103132. View

Aleanizy F, Mohmed N, Alqahtani F, Mohamed R . Outbreak of Middle East respiratory syndrome coronavirus in Saudi Arabia: a retrospective study. BMC Infect Dis. 2017; 17(1):23. PMC: 5217314. DOI: 10.1186/s12879-016-2137-3. View

Gomez C, Perdiguero B, Jimenez V, Filali-Mouhim A, Ghneim K, Haddad E . Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. PLoS One. 2012; 7(4):e35485. PMC: 3334902. DOI: 10.1371/journal.pone.0035485. View

Kreijtz J, Suezer Y, van Amerongen G, de Mutsert G, Schnierle B, Wood J . Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis. 2007; 195(11):1598-606. DOI: 10.1086/517614. View

Singh M, Cattaneo R, Billeter M . A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol. 1999; 73(6):4823-8. PMC: 112525. DOI: 10.1128/JVI.73.6.4823-4828.1999. View

Chen K, Wu X, Yu D, Ou H, Li Y, Zhou Y . Process optimization for the rapid production of adenoviral vectors for clinical trials in a disposable bioreactor system. Appl Microbiol Biotechnol. 2018; 102(15):6469-6477. DOI: 10.1007/s00253-018-9091-5. View

Feng L, Wang Q, Shan C, Yang C, Feng Y, Wu J . An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nat Commun. 2020; 11(1):4207. PMC: 7442803. DOI: 10.1038/s41467-020-18077-5. View

van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J, Port J . ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020; 586(7830):578-582. PMC: 8436420. DOI: 10.1038/s41586-020-2608-y. View

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

10.

Xiong C, Levis R, Shen P, Schlesinger S, Rice C, Huang H . Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science. 1989; 243(4895):1188-91. DOI: 10.1126/science.2922607. View

11.

Lundstrom K . Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. Viruses. 2020; 12(11). PMC: 7698750. DOI: 10.3390/v12111324. View

12.

Higgins T, Wu A, Illing E, Sokoloski K, Weaver B, Anthony B . Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review. Otolaryngol Head Neck Surg. 2020; 163(4):682-694. DOI: 10.1177/0194599820933170. View

13.

Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C . Rescue of measles viruses from cloned DNA. EMBO J. 1995; 14(23):5773-84. PMC: 394696. DOI: 10.1002/j.1460-2075.1995.tb00266.x. View

14.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

15.

Kay M, Glorioso J, Naldini L . Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001; 7(1):33-40. DOI: 10.1038/83324. View

16.

Mahase E . Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ. 2021; 372:n296. DOI: 10.1136/bmj.n296. View

17.

Ohara S, Inoue K, Yamada M, Yamawaki T, Koganezawa N, Tsutsui K . Dual transneuronal tracing in the rat entorhinal-hippocampal circuit by intracerebral injection of recombinant rabies virus vectors. Front Neuroanat. 2009; 3:1. PMC: 2629710. DOI: 10.3389/neuro.05.001.2009. View

18.

Lundstrom K . Coronavirus Pandemic-Therapy and Vaccines. Biomedicines. 2020; 8(5). PMC: 7277397. DOI: 10.3390/biomedicines8050109. View

19.

Sun W, McCroskery S, Liu W, Leist S, Liu Y, Albrecht R . A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines (Basel). 2020; 8(4). PMC: 7766959. DOI: 10.3390/vaccines8040771. View

20.

Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias C . Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021; 27(4):620-621. DOI: 10.1038/s41591-021-01270-4. View